Open Terminal →

Analyses / PFE

PFE Pfizer Inc. As of Nov 19, 2026
$28.06

Large-cap pharma at $28.06 with a 5.4% dividend yield. Earnings and revenue are declining, and the payout ratio is above 100%.

Setup: Value and income, recovery watch Confidence: medium Horizon: 1-3 months Risk: medium Category: Large Cap Value and Income
🔒 Trade Plan — entry · target · stop
Entry Zone
$•••–•••
Target
$•••
Stop Loss
$•••
Risk / Reward
•.• : 1
Unlock the exact levels — free →

A free account reveals PFE's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Forward P/E of 20.6x is well below the trailing 39.8x, which suggests the market may expect earnings to normalize. Gross margin of 75.8% and operating margin of 15.0% show a high-margin base. Shares trade 57% of the way up the 52-week range with a 5.4% dividend yield. Insider transactions skew toward buying (77 buys vs 27 sells, about 3.5M shares bought vs 1.6M sold). Beta of 0.29 implies low sensitivity to broad market moves.

▼ Bear Case

Revenue fell 14.8% and EPS fell 37.1% year over year, so the trailing P/E of 39.8x reflects shrinking earnings. The payout ratio of 125.8% means the dividend exceeds reported earnings, which could pressure the payout if earnings do not recover. Quick ratio of 0.87 is below 1.0. Debt-to-equity and interest coverage are unavailable in the data, so balance sheet strain cannot be fully assessed. The stock is 2.6% above its 52-week low.

Valuation

MIXED VALUE — score 58/100

Forward multiples look reasonable, but trailing P/E is elevated because earnings are falling. Dividend yield is high but not covered by earnings.

Technical Levels

Support · $28.00 (Day low) · $23.62 (52-week low)

Resistance · $28.47 (Prior close) · $31.44 (52-week high)

RSI: Not available in provider data

Financial Health

Score 55/100. Liquidity is adequate on current ratio but thin on quick ratio. Payout exceeds earnings. Leverage cannot be fully assessed with current data.

Catalysts

Quarterly dividend payment (headline cites Dec. 7)Dec. 7 per headlineSupports income thesis if maintained
Next quarterly earnings reportDate not in provider dataHigh. Revenue trend and payout coverage are the key checks
China in vivo CAR-T licensing dealRecent per headlineLow to medium. Pipeline optionality, financial size not disclosed in data

Risk Flags

Revenue growth of -14.8% and EPS growth of -37.1% year over year.
Payout ratio of 125.8% exceeds earnings; dividend coverage is weak.
ROE, ROIC, debt-to-equity, RSI and free cash flow per share are null in the provider data.
Fundamentals, balance sheet, cash flow and sentiment fields are null, so coverage is thin.
News timestamps appear unusual; verify dates against source before relying on timing.

See PFE's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock PFE free →

Recent News

More Analyses

PFE FAQ

Is PFE a buy right now?

Pfizer Inc.'s current read is a Value and income, recovery watch setup with medium confidence over a 1-3 months horizon. Valuation: MIXED VALUE. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is PFE overvalued?

MIXED VALUE (valuation score 58/100). Forward multiples look reasonable, but trailing P/E is elevated because earnings are falling. Dividend yield is high but not covered by earnings.

What are the risks of buying PFE?

Revenue fell 14.8% and EPS fell 37.1% year over year, so the trailing P/E of 39.8x reflects shrinking earnings. The payout ratio of 125.8% means the dividend exceeds reported earnings, which could pressure the payout if earnings do not recover. Quick ratio of 0.87 is below 1.0. Debt-to-equity and interest coverage are unavailable in the data, so balance sheet strain cannot be fully assessed. The stock is 2.6% above its 52-week low.